CN116898902A - Pharmaceutical composition for preventing and treating coronavirus infection - Google Patents
Pharmaceutical composition for preventing and treating coronavirus infection Download PDFInfo
- Publication number
- CN116898902A CN116898902A CN202310188887.0A CN202310188887A CN116898902A CN 116898902 A CN116898902 A CN 116898902A CN 202310188887 A CN202310188887 A CN 202310188887A CN 116898902 A CN116898902 A CN 116898902A
- Authority
- CN
- China
- Prior art keywords
- radix
- pharmaceutical composition
- herba schizonepetae
- gypsum
- fructus forsythiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 24
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 11
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims abstract description 11
- 241000711573 Coronaviridae Species 0.000 claims description 38
- 230000000840 anti-viral effect Effects 0.000 claims description 29
- 235000003130 Arctium lappa Nutrition 0.000 claims description 16
- 235000008078 Arctium minus Nutrition 0.000 claims description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 15
- 239000010440 gypsum Substances 0.000 claims description 14
- 229910052602 gypsum Inorganic materials 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 10
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 8
- 235000011477 liquorice Nutrition 0.000 claims description 7
- 235000013376 functional food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241001678559 COVID-19 virus Species 0.000 claims description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 241000208843 Arctium Species 0.000 claims 3
- 239000008213 purified water Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 240000005528 Arctium lappa Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 235000013399 edible fruits Nutrition 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 241000315672 SARS coronavirus Species 0.000 description 11
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 235000006751 Platycodon Nutrition 0.000 description 7
- 241000951473 Schizonepeta Species 0.000 description 7
- -1 anti-inflammatory Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 229930189914 platycodon Natural products 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 240000003582 Platycodon grandiflorus Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 description 5
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 5
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 206010063659 Aversion Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000555712 Forsythia Species 0.000 description 4
- 241000229179 Ledebouriella Species 0.000 description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000576429 Forsythia suspensa Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011045 prefiltration Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000008904 Betacoronavirus Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 241000207834 Oleaceae Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241001180876 Saposhnikovia Species 0.000 description 2
- 241001180873 Saposhnikovia divaricata Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 108010028403 hemagglutinin esterase Proteins 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001198934 Forsythia viridissima Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000282375 Herpestidae Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000229182 Ledebouriella seseloides Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001061076 Melanonus zugmayeri Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010021888 Nervous system infections Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- 229930185474 acteoside Natural products 0.000 description 1
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses a pharmaceutical composition for preventing and treating coronavirus infection. The pharmaceutical composition of an embodiment of the application comprises mixed extracts of radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum or fractions thereof.
Description
Technical Field
The present application relates to a pharmaceutical composition for preventing and treating coronavirus infection, and more particularly, to a pharmaceutical composition for preventing and treating coronavirus infection comprising a Jiufeng detoxification soup extract as an active ingredient.
Background
Coronaviruses (coronaviruses) were first found in chickens in 1937 and then in animals such as pigs, dogs, birds, etc., and by 1965 in humans. Such a name is given to a pattern similar to a corona phenomenon in which a rear edge portion of a solar light bulb is shielded by a moon to emit white light when a person is on a full day.
Coronaviruses are known to induce mainly pneumonia and enteritis, or also nervous system infections and hepatitis in humans and animals. Coronaviruses belong to the family Coronaviridae (Coronaviridae), have a spherical outer membrane, and are sense ribonucleic acid (positive sense RNA) viruses of about 100nm-120nm in size (Master, 2006). Coronaviruses are formed from five structural proteins, namely the most coat spike protein (S), hemagglutinin-esterase (HE) protein, transmembrane (M) protein, small membrane (E) protein, and nucleocapsid (N) protein (Lai and Homes,2001.Fields Virology). Among them, spike proteins, which act as ligands binding to cellular receptors and induce fusion between host cells and viruses, are known as the most mutated proteins.
Conventionally, coronaviruses are considered to be hardly infectious to humans, but mainly infectious to pathogenic bacteria of animals such as dogs, pigs, and cattle. Even if a human is infected, only one of many viruses inducing respiratory symptoms induces intestinal diseases such as cold and diarrhea with low risk in children. Until the etiology of Middle East Respiratory Syndrome (MERS), which causes hundreds and thousands of deaths worldwide, has been ascertained to be a novel (variant) coronavirus, there is growing interest.
Middle east respiratory syndrome was originally discovered in sauter arabia in 2012, and is a disease that develops severe respiratory symptoms such as hyperpyrexia, cough, dyspnea, etc., and is accompanied by complications and death under severe conditions. Although no clear source and route of infection is identified, it is reported that infection is highly likely by contact with camels in the middle east and can be transmitted by close contact between humans. Patients mainly concentrated in the middle east and more than 100 infected persons appear in the korean universe starting from 5 months 2015.
As described above, it is known that the middle east respiratory syndrome and severe acute respiratory syndrome are each caused by a mutant coronavirus (middle east respiratory syndrome-coronavirus, severe acute respiratory syndrome-coronavirus, and severe acute respiratory syndrome coronavirus type 2) belonging to the genus B coronavirus (Beta coronavirus). Thus, the middle east respiratory syndrome-coronavirus, severe acute respiratory syndrome-coronavirus, and severe acute respiratory syndrome coronavirus type 2 share similar characteristics in terms of clinical symptoms, etiology, and infection. In the phylogenetic tree (phylogenetic tree), severe acute respiratory syndrome-coronavirus and severe acute respiratory syndrome coronavirus type 2 belong to a system B including bat-derived coronaviruses that are different from bat-severe acute respiratory syndrome-like coronaviruses, and middle east respiratory syndrome-coronavirus belongs to a system C including bat-derived coronaviruses (Trends Microbiol 24:490-502; https:// nextstreain.org/groups/blab/sams-like-covf_virus_type = SARS-CoV-2).
The middle east respiratory syndrome-coronavirus, severe acute respiratory syndrome-coronavirus, and severe acute respiratory syndrome coronavirus type 2 are all considered to originate from bats (anti-viral Res 101:45-56) as primary hosts for a variety of coronaviruses, and their clear routes of infection have not been clarified to date. On the other hand, it is believed that the above-mentioned viruses increase the possibility of co-infection of humans and animals (Nat Rev Microbiol 14:523-534) against the interspecies infections of the cat (palm civet) and the dromedary camel (dromedary camel), and nosocomial infections are the main cause of infection of the middle east respiratory syndrome, coronavirus, and severe acute respiratory syndrome, coronavirus, between humans (BMC Med 13:1-12).
On the other hand, although therapeutic agents for severe acute respiratory syndrome coronavirus type 2 are now being developed, they have been mainly developed centering on compounds or existing medicinal materials, and natural substance therapeutic agents have not been developed yet.
In particular, antiviral agents developed so far exhibit serious side effects, and their use requires much attention. Currently, these therapeutic agents have poor efficacy and side effects. Therefore, there is an increasing need to develop an excellent novel coronavirus therapeutic agent for preventing and treating the occurrence of coronaviruses, which has a remarkable infection-inhibiting effect and little toxicity.
Under such circumstances, the present inventors have continued efforts to develop a novel coronavirus therapeutic agent, and have confirmed that a mixed extract of saposhnikovia divaricata, burdock, forsythia suspensa, schizonepeta, notopterygium root, licorice root, platycodon root and gypsum, which has a superior effect of inhibiting the proliferation of severe acute respiratory syndrome coronavirus type 2, severe acute respiratory syndrome coronavirus and middle eastern respiratory syndrome coronavirus, has been accomplished.
Prior art literature
Patent literature
Patent document 1: korean laid-open patent publication No. 2022-0044082
Disclosure of Invention
Technical problem to be solved
The embodiment of the application provides an antiviral pharmaceutical composition for coronaviruses comprising mixed extracts of radix sileris, burdock, fructus forsythiae, herba schizonepetae, notopterygium root, liquorice, platycodon grandiflorum and gypsum or fractions thereof and a pharmaceutical composition for preventing and treating coronavirus infection.
Technical proposal for solving the problems
The application provides the following technical scheme.
The antiviral pharmaceutical composition for coronavirus according to an embodiment of the present application comprises a mixed extract of radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum or fractions thereof.
Also, according to an embodiment of the present application, there is provided an antiviral pharmaceutical composition for coronaviruses extracted by mixing the above-mentioned ledebouriella root, burdock fruit, forsythia fruit, schizonepeta, notopterygium root, licorice root, platycodon root and gypsum in a weight ratio of 500:500:835:250:250:500:500:1665.
In addition, according to an embodiment of the present application, there is provided an antiviral pharmaceutical composition for coronaviruses concentrated by adding 8 to 10 times of pure water to the mixed weight of the above-mentioned ledebouriella root, burdock fruit, forsythia fruit, schizonepeta, notopterygium root, licorice root, platycodon root and gypsum, extracting at 80 to 100 degrees for 2 to 3 hours, filtering, and concentrating the filtrate under reduced pressure at 60 degrees or less.
Also, according to an embodiment of the present application, there is provided an antiviral pharmaceutical composition for coronaviruses further comprising lactose hydrate, silica, magnesium stearate.
The application has the beneficial effects that:
the embodiment of the application comprises the mixed extracts or the fractions thereof of the divaricate saposhnikovia root, the burdock, the fructus forsythiae, the herba schizonepetae, the notopterygium root, the liquorice, the platycodon root and the gypsum, has antiviral effect on coronaviruses and has the effect of preventing and treating coronavirus infection.
Drawings
Fig. 1 to 4 are experimental result images showing the antiviral effect of the embodiment.
Fig. 5 and 6 are images showing experimental results of cell survival effects of examples.
Fig. 7 to 9 are experimental results images showing cytotoxicity and effective drug effect concentration of the examples.
Fig. 10 is an experimental result image showing the effective pharmacodynamic concentration of the positive control group.
Detailed Description
The present application will be further understood by the following examples. However, the following examples are merely illustrative of the present application, and the scope of the present application is not limited to the following examples. The embodiments of the present application are provided to more fully explain the present application to those skilled in the art to which the present application pertains. The present application is not limited to the embodiments set forth herein, but may be embodied in other forms.
The application relates to an antiviral pharmaceutical composition for coronavirus and a pharmaceutical composition for preventing and treating coronavirus infection, which comprises mixed extracts of radix sileris, burdock, fructus forsythiae, herba schizonepetae, notopterygium root, liquorice, balloonflower root and gypsum or fractional products thereof.
An embodiment of the present application may be an antiviral pharmaceutical composition comprising a Jiufeng Jiedu decoction extract as an active ingredient, and a pharmaceutical composition for preventing and treating coronavirus infection.
Jiufeng Jiedu decoction is one kind of otorhinolaryngological preparation for treating tonsillitis and other laryngopharynx swelling and pain.
The present inventors have confirmed a novel effect and use of a composition containing an extract of Jiufeng Jiedu decoction as an active ingredient, which has an antiviral effect against a novel coronavirus, and have developed a pharmaceutical composition for use in the prevention and treatment of coronavirus infection.
For example, the Jiufeng Jiedu decoction refers to a mixed extract or fraction thereof containing radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum.
The term "Fangfeng (Ledebouriella seseloides WOLFF.)" in the present application is prepared using roots and rhizomes of Fangfeng (Saposhnikovia divaricata Schiskin) of Umbelliferae, and has special odor, pungent, sweet and warm properties. It is effective in treating all wind diseases such as headache, aversion to cold, fever, general pain, and sore throat, and can be used for treating limb joint pain due to wind-cold-dampness, tetanus, muscle spasm, hemiplegia due to apoplexy, paralysis pain, skin pruritus, tinea, etc. Further, pharmacological actions are reported to be antipyretic, anti-inflammatory, sedative, immune-activating, antiallergic, antiulcer, antibacterial, skin-improving bacteria inhibitory, etc.
The term "burdock fruit" is the fruit of burdock Arctium lappa, and is a medicinal material with the effects of dispelling wind and heat, ventilating lung, eliminating swelling after acne and eruption and detoxifying.
Fructus Arctii refers to mature seeds of the biennial herb burdock (Arctium lappa Linne) belonging to the family Chrysanthemum (Compositae).
The term "fructus forsythiae" of the application is a fruit of golden bell flower (Forsythia Viridissima Lindley) or fructus forsythiae (Forsythia suspensa Vahi) belonging to the Oleaceae family (Oleaceae), which has special smell, bitter taste and slightly cool nature. Fructus forsythiae has effects of relieving fever and removing toxic substances, can be used for treating high fever and absentmindedness at the early stage of warm diseases, and can be used for treating abscess, macula, proctitis, lung abscess, lymphadenitis, pharyngolaryngitis, etc., and has diuretic and antiinflammatory effects. Also, it is known that it has pharmacological actions such as antibacterial action, anti-inflammatory action, blood pressure lowering, hemostatic action, liver treating action, antipyretic, antiemetic and diuretic actions.
The term "herba schizonepetae (Schizonepeta rhizome)" of the present application is a term annual herb of Labiatae, and whole herb is used as a medicinal material. The medicinal effect has antipyretic effect, so that the Chinese medicinal composition is used for sweating and relieving fever at the early stage of cold, is used for treating diseases such as sphagitis, skin diseases and apoplexy, and is fried to black to have hemostatic effect, and is applied to symptoms such as uterine bleeding, epistaxis, fecal bleeding, hematemesis and urinary hemorrhage.
The term "Notopterygium root" of the present application has strong dispersing effect, and thus, it is used in diseases such as exogenous headache, aversion to cold, fever, etc., and in diseases such as arthralgia, muscle spasm paralysis, shoulder pain, facial distortion, skin ulcer, aversion to cold, fever, pain, etc. in the early stage of sore and rash. The pharmacological effects include relieving fever, relieving pain, inhibiting dermatophytes, and increasing myocardial blood flow.
The term "licorice (Glycyrrhiza uralensis Fischer or Glycyrrhiza glabra l.)" in the present application is a perennial herb of the order rosaceous, a dicotyledon plant, which has a special smell and a sweet taste. Licorice shows good curative effect by regulating toxicity of all medicines, and has effects of regulating cold and heat of viscera and pathogenic qi, dredging all blood vessels and strengthening musculoskeletal. The pharmacological effects have detoxification effects, are effective in hepatitis, urticaria, dermatitis, eczema and the like, and are known to have antitussive, expectorant, muscle relaxing, diuretic, antiinflammatory effects, and peptic ulcer inhibiting effects.
The term "platycodon grandiflorum" is a medicinal material prepared from root or peel of platycodon grandiflorum (Platycodon grandiflorum A. De Candolle) of platycodon grandiflorum, and has slightly odorous, bitter and flat taste. It is used in treating cough, expectoration, nasal obstruction, asthma, bronchitis, pleurisy, headache, aversion to cold, tonsillitis, etc. caused by laryngopharynx pain and common cold, and has the effects of eliminating phlegm, lowering blood sugar, lowering cholesterol, and improving bacteria inhibition.
The chemical component of the term "gypsum" according to the application is CaSO 4 ·2H 2 O. Diamond plate-shaped or columnar crystals are formed, occasionally gathered into a chrysanthemum shape, and double crystals in the shape of arrow tails are formed. In addition, there are many cases where a sheet-like, fibrous, block-like, dense agglomerate is formed, and especially, a parallel aggregate formed into a fibrous form is called fibrous gypsum, and a dense aggregate of fine particles is called anhydrite.
For example, the radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum may be mixed at a weight ratio of 400-600:400-600:800-850:200-300:200-300:400-600:1600-1700, and the radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum may be mixed at a weight ratio of 500:500:835:250:250:500:500:1665.
For example, the filtrate may be concentrated under reduced pressure at a temperature of 60 ℃ or less by adding 8 to 10 times of pure water to the mixture of the above-mentioned radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum, extracting at a temperature of 80 to 100 ℃ for 2 to 3 hours, and filtering.
Lactose hydrate, silica, magnesium stearate, for example, may also be included.
According to an embodiment of the present application, an antiviral effect against coronaviruses may be provided by including a mixed extract of ledebouriella root, burdock fruit, forsythia fruit, schizonepeta, notopterygium root, licorice root, platycodon root and gypsum or fractions thereof, which may have an effect for preventing and treating coronavirus infection.
By "preventing" is meant inhibiting or delaying all actions of coronavirus expression.
The term "treatment" as used herein refers to any action that alters the symptoms of an individual suspected of having a coronavirus infection or pathogenesis to improvement or cure.
The above pharmaceutical composition may comprise the active ingredient alone or may comprise one or more pharmaceutically acceptable carriers, excipients or diluents to provide a pharmaceutical composition.
The term "pharmaceutically acceptable" as used herein refers to a property that exhibits no toxicity to cells or humans exposed to the combination.
Furthermore, the above pharmaceutical composition may be provided in admixture with a conventionally known coronavirus therapeutic substance. That is, the above-mentioned pharmaceutical composition may be administered in parallel with a known compound having an effect of preventing or treating coronavirus.
The term "administration" refers to the administration of a prescribed substance to an individual by an appropriate method, and "individual" refers to all animals including humans, mice, living mice, and domestic animals that have been or are able to be infected with coronavirus. Specifically, it may be, for example, a mammal including a human.
The administration route of the above-mentioned pharmaceutical composition includes oral, intravenous, intramuscular, intraarterial, intramedullary, epidural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal, but is not limited thereto.
The pharmaceutical composition may be administered orally or parenterally, and when administered parenterally, injection modes such as external or intraperitoneal injection, intrajob injection, subcutaneous injection, intravenous injection, intramuscular injection, and intrathoracic injection are preferably selected, but not limited thereto, and oral administration may be preferably selected from the viewpoint of selecting a more effective absorption route.
The preferred amount of the above-mentioned pharmaceutical composition to be administered varies depending on the state of the patient, the body weight, the severity of the disease, the pharmaceutical form, the route of administration and the period, and can be appropriately selected by the relevant practitioner. For example, the composition may be administered at 10mg/kg/day to 1000mg/kg/day, and suitably at 200mg/kg/day to 900mg/kg/day, but is not limited thereto. The administration may be performed once a day or divided into several administrations. The above-described amounts of administration are not limiting in any respect.
In the case of preparing the above pharmaceutical composition, it is prepared using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, etc., which are generally used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations are prepared by mixing the above extract with one or more excipients, for example, with starch, calcium carbonate (calcium carbonate), sucrose (sucrose) or lactose (lactose), gelatin and the like. Besides the simple excipient, a lubricant such as magnesium stearate and talc is used. Liquid preparations for oral administration may contain various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to water, liquid paraffin, which are common simple diluents, for example, suspending agents, internal solutions, emulsions, syrups, etc. Formulations for parenteral administration include sterilized aqueous solutions, nonaqueous solvents, suspending agents, oils, freeze-dried formulations, suppositories and the like. As the nonaqueous solvent and suspending agent, injectable esters such as propylene glycol (propylene glycol), vegetable oils such as polyethylene glycol and olive oil, and ethyl oleate can be used. As a base for suppositories, witepsol, polyethylene glycol, tween (tween) 61, cocoa butter, glycerol laurate, glycerol gelatin and the like can be used.
According to other embodiments of the present application, a health functional food for preventing and improving coronavirus infection is provided comprising a mixed extract of ledebouriella root, burdock fruit, forsythia fruit, schizonepeta, notopterygium root, licorice root, platycodon root and gypsum or fractions thereof.
The health functional food may further comprise one or more of carrier, diluent, excipient and additive, and is formulated into one dosage form selected from the group consisting of tablet, pill, powder, granule, powder, capsule and liquid. The food may be added with acteoside or its pharmaceutically acceptable salt, such as various foods, powder, granule, tablet, capsule, syrup, beverage, chewing gum, tea, vitamin complex, health food, etc.
The additive that may be contained in the health functional food may be one or more selected from the group consisting of natural carbohydrates, flavoring agents, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), coloring agents, fillers (cheese, chocolate, etc.), pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents, and pulp.
Examples of the above natural carbohydrates are monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, and the like; and polysaccharides such as usual sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. The above flavoring agent may advantageously use natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside a, glycyrrhizic acid, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.). In addition, various nutrients, vitamins, minerals (electrolytes), synthetic flavors, natural flavors, colorants, thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, etc. may be contained. In addition, the health functional food may contain pulp for preparing natural juice and vegetable beverage. These components may be used singly or in combination.
Preferably, specific examples of the carrier, excipient, diluent and additive include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, methylcellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.
In the case of preparing the above health functional food, it can be prepared using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, etc., which are generally used.
The coronavirus is not particularly limited as long as it can be covered by one of ordinary skill in the art to which the present application pertains, and may be SARS-CoV-2Omicron, as appropriate.
As described above, although the exemplary embodiments of the present application have been described, the present application is not limited thereto, and it will be understood by those skilled in the art that various changes and modifications may be made without departing from the concept and scope of the appended claims.
Examples
Preparation examples antiviral pharmaceutical compositions concerning coronaviruses were prepared.
1. Preparing a dry extract
Respectively placing 500mg of radix Saposhnikoviae, 500mg of fructus Arctii, 835mg of fructus forsythiae, 250mg of herba Schizonepetae, 250mg of Notopterygii rhizoma, 250mg of Glycyrrhrizae radix, 500mg of radix Platycodi and 1685mg of Gypsum Fibrosum into an extractor to extract. In this case, the pure water was contained in an amount 8 times that of each raw material, and extraction was carried out at a temperature of 100℃for 3 hours. Next, the extract extracted in the extractor was filtered using 100 mesh (mesh) and moved to a thickener, and then concentrated under reduced pressure at a temperature of 60 ℃ or lower so that the drying loss was 50%. Then, the concentrated concentrate was dried under reduced pressure at a temperature of 70℃or lower and a pressure of 36 to 76 cmHg. Next, a step of pulverizing the dried product dried under reduced pressure using the pulverizing net of 1.2 was performed.
For each of the dried materials prepared by the above method, 10.48 weight percent of divaricate saposhnikovia root, 10.48 weight percent of burdock fruit, 17.51 weight percent of burdock fruit, 5.24 weight percent of fineleaf schizonepeta herb, 5.24 weight percent of notopterygium root, 5.24 weight percent of liquorice, 10.48 weight percent of platycodon root and 35.32 weight percent of gypsum are mixed to prepare the medicament taking the dried extract of the Jiufeng Jiedu decoction as the main component.
2. Preparation of pharmaceutical compositions
The dry extract prepared in the above preparation example 1, an excipient, a lubricant and a capsule were mixed to prepare a pharmaceutical composition in the form of a capsule.
Specifically, the lactose hydrate and silica as excipients were mixed with the dried extract and then filled into capsules with magnesium stearate as a lubricant, and the mixture was prepared according to the capsule preparation method in the general formulation rule of korean pharmacopoeia.
Experimental examples in vitro (in vitro) antiviral efficacy assessment
The efficacy of the pharmaceutical preparation of the above preparation in inhibiting SARS-CoV-2WT and SARS-CoV-2Omicron was confirmed by using Vero E6 cells as cells capable of confirming cytopathic effect (cytopathic effect) due to apoptosis after infection.
SARS-CoV-2WT (Betacoronavirus, scade, NCCP 43326/2020/Korea) used in the experiment was obtained from Korean national pathogen resource Bank as TCID 50 50 μl based dilution to 100TCID 50 50 μl was used, and antiviral efficacy against Vero E6 cells was evaluated using the dried extract as the pharmaceutical agent prepared by the above preparation example 1.
1. Viral infection and pharmaceutical treatment
In 96-well (well) cell culture plates, prepared Vero E6 cells were grown at 2X 10 4 After 24 hours (h) of incubation at cell/well concentration, vero E6 cell supernatants were removed and the cells were washed (washinging) using Dulcit Modified Eagle Medium (DMEM) containing 0% Fetal Bovine Serum (FBS).
Next, SARS-CoV-2 and SARS-CoV-2Omicron virus were adjusted to 100TCID 50 A concentration of 50. Mu.l was used to infect 50. Mu.l per well. The infected cells were cultured (incubation) in a cell culture apparatus at 37℃for 1 hour. Then, 150. Mu.l of Du's modified Igor's medium containing 2% fetal bovine serum and a drug diluted to a different concentration was used in place of the medium at 37℃and 5% CO 2 Is cultured under the condition of (2) for 4 days.
Also, the agents used in the experimental examples included a Filtration (Filtration) process using a 0.22 μm filter after diluting the dried extract prepared by the above preparation example 1 with a Phosphate Buffer Solution (PBS) containing 10% dimethyl sulfoxide (DMSO).
2. Antiviral efficacy was confirmed by Staining (Staining)
Confirmation of antiviral efficacy by staining was performed by staining cells with crystal violet (crystal violet).
Specifically, vero E6 cells infected with virus and treated with various concentrations of the agent in the above experimental example 1 were stained with 0.05% crystal violet in an amount of 1ml/well for 10 minutes and then washed, and the results were observed by measuring absorbance at a wavelength of 570 nm.
In the results using crystal violet staining, the stained portion of the cells was judged as a portion exhibiting virus inhibitory efficacy, and the unstained portion was judged as a portion not exhibiting inhibitory efficacy or exhibiting cytotoxicity.
Furthermore, radevir (RDV, remdesired) was used as a positive control group, and pure Vero E6 cells containing no virus and drug were used as a negative control group (100 TCID or NC).
2-1. One evaluation
In one evaluation, the above-mentioned agents were prepared to a concentration of 500mg/ml, and used with a phosphate buffer solution containing 10% dimethyl sulfoxide at 1/10 dilution, starting from 50mg/ml, and diluted 2-fold (2-fold) for experiments.
Specifically, the above-mentioned agent after filtration including the step of filtration in a 0.22 μm filter was compared with the pre-filtration and negative control group including no filtration step of the filter.
Referring to FIG. 1, it was confirmed that the antiviral efficacy of the agent was not exhibited for SARS-CoV-2 WT.
Referring to FIG. 2, it was confirmed that the antiviral effect against SARS-CoV-2Omicron was exhibited at a concentration of 6.25mg/ml to 12.5 mg/ml.
2-2. Second evaluation
In the second evaluation, the above-mentioned agent was prepared to a concentration of 500mg/ml, diluted with a phosphate buffer solution containing 10% dimethyl sulfoxide, and used, starting from 250mg/ml, and diluted in 3-fold dilution (3-fold dilution) to conduct an experiment.
Specifically, the case of using the above-described agent was compared with a positive control group and a negative control group using 50 μm of adefovir (RDV).
Referring to FIG. 3, it was confirmed that the antiviral efficacy of the agent was not exhibited for SARS-CoV-2 WT.
Referring to FIG. 4, in the case of SARS-CoV-2Omicron, cell survival was observed in the case of treating the drug at a concentration of 1.03mg/ml to 3.09mg/ml, and thus it was confirmed that the antiviral effect was exhibited.
3. Assessment of cytotoxicity
It was confirmed whether the agent prepared according to the preparation example induces cytotoxicity in Vero E6 cells. Specifically, vero E6 cells prepared in 96 well cell culture plates were grown at 2X 10 4 After 24 hours of cell/well incubation, the supernatant of Vero E6 cells was removed and the cells were washed with doe's modified eagle medium containing 0% fetal bovine serum.
Next, 150. Mu.l of a culture medium containing a drug diluted to a different concentration in Du's modified Igor's medium containing 2% fetal bovine serum was used for replacement, and the mixture was subjected to a dilution with 5% CO at 37 ℃C 2 After 4 hours of incubation under the conditions of (2) the crystal violet staining results were confirmed.
The dyeing method using crystal violet was the same as in experimental example 2 above.
3.1. One time evaluation 1
In one evaluation, the above-mentioned agents were prepared to a concentration of 500mg/ml, and used with a phosphate buffer solution containing 10% dimethyl sulfoxide at 1/10 dilution, starting from 50mg/ml, and diluted 2-fold for the experiment.
Specifically, the above-mentioned agent after filtration including the step of filtration in a 0.22 μm filter was compared with the pre-filtration and negative control group including no filtration step of the filter.
As shown in FIG. 5, the survival of cells was confirmed at a concentration of 12.5mg/ml or less, and the generation of a precipitate was confirmed in the case of using a drug for filtration.
3.2. Secondary evaluation
In the second evaluation, the above-mentioned agent was prepared to a concentration of 500mg/ml, diluted with a phosphate buffer solution containing 10% dimethyl sulfoxide, and used, starting from 250mg/ml, diluted in a 3-fold dilution manner to conduct an experiment.
Specifically, the case of using the above-mentioned drug was compared with the negative control group, and as shown in FIG. 6, cell survival was confirmed at a concentration of 1.03mg/ml or less until some cytotoxicity occurred at a concentration of 3.09 mg/ml.
3.3. Confirmation of dyeing site
The filtered above-mentioned agent including the step of filtering in the 0.22 μm filter was compared with the pre-filtration and negative control group including no filter step to confirm whether or not the precipitate was generated.
Specifically, CC 50 Shows cytotoxicity of the relevant agents, EC 50 The relative amounts of viruses inhibited by the agents are shown for effective pharmacodynamic concentrations of the agents.
As shown in fig. 7 and 8, it was confirmed that the cells were not stained with crystal violet at a high concentration, but the precipitate was found to be present without filtration.
3.4.EC 50 CC (CC) 50 Comprehensive evaluation of (2)
FIG. 9 is a comprehensive view showing cytotoxicity (CC 50 ) Concentration of effective drug (EC) 50 ) When the above-mentioned drug was used at a concentration of 0.343mg/ml to 250mg/ml, it was confirmed that a part of cytotoxicity (CC) was exhibited at a concentration of 3.09mg/ml 50 ) Shows effective drug effect concentration at 0.907mg/ml (EC 50 ) Further, the s.i. (selection index (Selectivity Index), CC of the above-described pharmaceutical agent can be confirmed 50 /EC 50 ) The value shows 3.41.
FIG. 10 is a graph showing the effective drug Effect Concentration (EC) of positive control groups using 0.1. Mu.M to 50. Mu.M of Rede-Sivir 50 ) It was confirmed that the effective drug effect concentration was exhibited at a concentration of 3.125. Mu.M.
Therefore, referring to the above experimental examples, it was confirmed that the pharmaceutical preparation prepared according to the above preparation example exhibited antiviral effects against SARS-CoV-2Omicron (NCCP 43408/2021/Korea).
Claims (8)
1. An antiviral pharmaceutical composition for coronaviruses, which is characterized by comprising a mixed extract of radix sileris, burdock, fructus forsythiae, herba schizonepetae, notopterygium root, liquorice, platycodon grandiflorum and gypsum or a fraction thereof.
2. The antiviral pharmaceutical composition according to claim 1, wherein the radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum are mixed at a weight ratio of 400-600:400-600:800-850:200-300:200-300:400-600:1600-1700.
3. The antiviral pharmaceutical composition according to claim 2, wherein the radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum are mixed at a weight ratio of 500:500:835:250:250:250:500:1665.
4. The antiviral pharmaceutical composition according to claim 2, wherein the purified water is added in an amount of 8 to 10 times the weight of the mixture of the radix Saposhnikoviae, fructus Arctii, fructus forsythiae, herba Schizonepetae, notopterygii rhizoma, glycyrrhrizae radix, radix Platycodi and Gypsum Fibrosum, and the mixture is extracted at a temperature of 80 to 100 ℃ for 2 to 3 hours, filtered, and the filtrate is concentrated under reduced pressure at a temperature of 60 ℃ or less.
5. The antiviral pharmaceutical composition according to claim 1, further comprising lactose hydrate, silica, magnesium stearate.
6. The antiviral pharmaceutical composition for coronaviruses according to claim 1, which has an antiviral effect against SARS-CoV-2 Omicron.
7. A pharmaceutical composition for preventing and treating coronavirus infection is characterized by comprising mixed extracts of radix sileris, burdock, fructus forsythiae, herba schizonepetae, notopterygium root, liquorice, platycodon grandiflorum and gypsum or fractions thereof.
8. A health functional food for preventing and improving coronavirus infection is characterized by comprising mixed extracts of radix sileris, burdock, fructus forsythiae, herba schizonepetae, notopterygium root, liquorice, platycodon grandiflorum and gypsum or fractions thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2022-0045110 | 2022-04-12 | ||
| KR1020220088548A KR20230146971A (en) | 2022-04-12 | 2022-07-18 | Pharmaceutical composition for preventing or treating coronavirus infection |
| KR10-2022-0088548 | 2022-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116898902A true CN116898902A (en) | 2023-10-20 |
Family
ID=88358902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310188887.0A Withdrawn CN116898902A (en) | 2022-04-12 | 2023-02-22 | Pharmaceutical composition for preventing and treating coronavirus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116898902A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101023996A (en) * | 2007-03-26 | 2007-08-29 | 河南仲景药业股份有限公司 | Chinese medicine for treating exogenous epidemic disease and anemopyretic cold |
| CN111494502A (en) * | 2020-04-23 | 2020-08-07 | 徐修信 | Traditional Chinese medicine composition for early novel coronary virus pneumonia and preparation method thereof |
| CN111870657A (en) * | 2020-04-23 | 2020-11-03 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing coronavirus infection |
-
2023
- 2023-02-22 CN CN202310188887.0A patent/CN116898902A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101023996A (en) * | 2007-03-26 | 2007-08-29 | 河南仲景药业股份有限公司 | Chinese medicine for treating exogenous epidemic disease and anemopyretic cold |
| CN111494502A (en) * | 2020-04-23 | 2020-08-07 | 徐修信 | Traditional Chinese medicine composition for early novel coronary virus pneumonia and preparation method thereof |
| CN111870657A (en) * | 2020-04-23 | 2020-11-03 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing coronavirus infection |
Non-Patent Citations (1)
| Title |
|---|
| 德寿堂图书馆: "300首日本汉方大汇总，在日本各界力挺下日人医生汲取了中医这么多精辟……", pages 2, Retrieved from the Internet <URL:http://www.360doc.com/content/20/1201/16/53287542_948926920.shtml> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112274620B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia, preparation method, detection method and application thereof | |
| KR102640794B1 (en) | Composition for preventing or treating corona virus comprising herbal mixing extracts | |
| CN102552502B (en) | Traditional Chinese medicine for treating bacterial diseases in poultry | |
| CN102357154A (en) | Traditional Chinese medicine composition for preventing and treating avian infectious bronchitis and preparation method thereof | |
| JP2022545288A (en) | Tea composition for prevention, improvement or effect of respiratory disease and pharmaceutical composition containing the same | |
| KR101544470B1 (en) | Pharmaceutical composition and functional food for prevention or treatment of cancer comprising herbal extracts | |
| CN103800650B (en) | A kind of Chinese medicine for the treatment of removing heat from the lung and dissipating phlegm | |
| KR100527602B1 (en) | Composition comprising the extracts of Cucumis melon Linn. var. ma-gua, Ixeris dentata and Youngia sonchifolia for therapy against chronic viral hepatitis diseases | |
| KR101286463B1 (en) | A composition comprising extract of Cnidii Rhizoma for treating or preventing respiratory disease | |
| KR101474125B1 (en) | Composition comprising complex extract of Astragalus membranaceus BUNGE, Saposhnikovia divaricata Schiskin, Ostericum koreanum Maximowicz, Scutellaria baicalensis Georgi and Atractylodes japonica Koidz for preventing or treating asthma, bronchitis or pneumonia | |
| CN102764294B (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN103977372A (en) | Traditional Chinese medicine additive used for treating porcine epizootic diarrhea and preparing method thereof | |
| KR101286465B1 (en) | A composition comprising mixed herbal extract of Cnidii Rhizoma and Corydalis Tuber for treating or preventing respiratory disease | |
| CN101433658A (en) | Composition for preventing and treating chicken pox | |
| CN111632116A (en) | Preparation method of traditional Chinese medicine preparation for resisting viral cold | |
| CN104208453A (en) | Traditional Chinese medicine composition for preventing grass carp hemorrhagic disease and preparation method thereof | |
| CN116898902A (en) | Pharmaceutical composition for preventing and treating coronavirus infection | |
| Itharat et al. | Potential Thai herbal medicine for COVID-19 | |
| CN105055657A (en) | Spraying agent for improving pain caused by wisdom teeth and preparation method thereof | |
| Singh et al. | Herbal-based resources against exanthematous viral infections and other viral diseases | |
| KR20230146971A (en) | Pharmaceutical composition for preventing or treating coronavirus infection | |
| KR20110009732A (en) | A health care food comprising a polysaccharide having anti-rotavirus activity | |
| KR20230146972A (en) | Pharmaceutical composition for preventing or treating coronavirus infection | |
| KR100839099B1 (en) | Composition comprising an extract of galla rhois and moutan cortex radicis for preventing and treating the porcine epidemic diarrhea virus(pedv) | |
| KR100553982B1 (en) | Composition comprising the extracts of Cucumis melon Linn. var. ma-gua, Ixeris dentata and Youngia sonchifolia for therapy against chronic viral hepatitis diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20231020 |
|
| WW01 | Invention patent application withdrawn after publication |